Video

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of erdafitinib (Balversa) in urothelial carcinoma.

Erdafitinib, a novel targeted therapy that targets FGFR3-altered urothelial carcinoma, is a promising agent for patients with FGFR-driven disease, Siefker-Radtke says. In a phase 2 trial (NCT02365597), the drug demonstrated an overall response rate of 40% in patients with metastatic disease who had received prior chemotherapy, Siefker-Radtke explains.

As immunologically cold tumors appear to enrich FGFR3 alterations, determining optimal sequencing in patients with FGFR3-altered urothelial carcinoma is important, Siefker-Radtke notes. The phase 3 THOR trial (NCT03390504) is currently ongoing to determine whether these patients should receive erdafitinib or immune checkpoint inhibition first, Siefker-Radtke says. This trial is studying erdafitinib vs pembrolizumab (Keytruda) in patients with FGFR-altered advanced urothelial carcinoma who have received prior therapy, Siefker-Radtke concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP